Advance Cutting-Edge Research and Development with Next-Generation Targeted & Immune Therapies (mono & combination) and Learn How to Best Utilize them with Precision Oncology
The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication.
Arriving at a critical point for the NSCLC drug development field, as checkpoint inhibitors are on the brink of entering the perioperative setting and the targeted space is rapidly expanding, this forum will enable you to see a full picture of the developmental landscape and identify what MoAs and targets future biopharma investment will be put towards.
Network with 80+ expert drug developers over 3-days of comprehensive insights to uncover the latest industry knowledge on the molecular heterogeneity of lung cancer, the implications for therapeutic design when considering acquired resistance and optimal application of new drugs in the clinic.
2021 Speakers Included:
Vice President, Clinical Research Lead, External Collaborations Oncology Early Development
Merck and Co
Head of Clinical, Late Development Oncology R&D
AstraZeneca & European Commission’s Mission for Cancer, Board Member
Executive Director, Early Development Program Lead
Bristol Myers- Squibb
Who Attended in 2021?
Don't Just Take Our Word For It:
"The Non-Small Cell Lung Cancer Summit will be an important venue to learn more about the latest developments in lung cancer, including the emerging new treatments, and some of the informative new science."
Tony Jarkowski, Development Lead, Bristol-Myers Squibb
"The summit is an excellent lineup of talks and speakers. There have been rapid practice changing advances in NSCLC and the summit is a great way to stay abreast of the progress and cutting-edge science."
Kelly Covello, PHD, Head of Medical Affairs, Mirati Therapeutics Inc.